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Previously, we have demonstrated that keratinocyte releasable stratiﬁn, also known as 14-3-3 r protein, stimulates
matrix metalloproteinase (MMP)-1 expression in dermal ﬁbroblasts. In this study, we showed that stratiﬁn induced
ﬁbroblast MMP-1 messenger ribonucleic acid (mRNA) and protein levels through p38 mitogen-activated protein
kinase (MAPK). Our data indicated that treatment of dermal ﬁbroblasts with stratiﬁn resulted in rapid and transient
upregulation of c-jun and c-fos mRNA levels. We also demonstrated that SB203580 (SB), a specific inhibitor of p38
MAPK activity, inhibited the activation of ﬁbroblast MMP-1 mRNA expression by stratiﬁn. Subsequently, western
blot analysis revealed phosphorylation of p38 at 90 min after stratiﬁn stimulation and this was decreased to
approximately 50% of the maximum value by 120 min. Stratiﬁn was demonstrated to increase MMP-1 protein levels
starting at 4 h and reaching its peak at 12–24 h. Furthermore, SB significantly blocked the stratiﬁn induction of
MMP-1 protein levels (po0.005, n¼ 3). Microarray analysis of stratiﬁn-treated ﬁbroblasts shows an increase in
Elk4/Sap1 mRNA expression and this ﬁnding was conﬁrmed by northern blot analysis. Our results indicate that
stratiﬁn markedly increase Elk4/Sap1 mRNA expression in a time-dependent fashion. In conclusion, stratiﬁn stim-
ulates ﬁbroblast MMP-1 levels through the activation of c-fos and MAPK pathway.
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The matrix metalloproteinase (MMP) family consists of 25
zinc- and calcium-dependent proteinases in the mammalian
system. According to their substrate specificity, primary
structure, and cellular localization, MMP are subdivided into
five different classes: collagenases, gelatinases, stromely-
sins, matrilysins, and membrane-type MMP (Murphy et al,
2002). The basal expression of most MMP in cultured cells
is low, and these enzymes are transcriptionally induced by a
variety of growth factors, cytokines, and tumor promoters
(Birkedal-Hansen et al, 1993; Mauviel, 1993; Kahari and
Saarialho-Kere, 1997; Saarialho-Kere, 1998). Since MMP
are involved in extracellular matrix (ECM) turnover and con-
nective tissue remodeling, an imbalance in the expression
of MMP has been implicated in a number of pathological
conditions such as dermal fibrosis (Ghahary et al, 1996),
rheumatoid arthritis, atherosclerosis, pulmonary emphyse-
ma, and tumor invasion and metastasis (Birkedal-Hansen
et al, 1993; Nagase and Woessner, 1999).
Collagenase (MMP-1) is the principal fibroblast-derived
secreted proteinase capable of degrading native fibrillar
collagens of types I, II, III, and V. MMP-1 plays an important
role in the remodeling of collagenous connective tissues in
various physiological and pathological situations. A single
activator protein-1 (AP-1) element that is located at 65 to
72 in the promoter region of human MMP-1 gene plays an
essential role in the activation of MMP-1 gene transcription
in response to a variety of extracellular signals (Westerm-
arck and Kahari, 1999). Adjacent to the AP-1 binding site is
the E twenty-six (ETS) regulatory cis-element that also plays
a role in the regulation of AP-1-dependent MMP-1 gene
transcription (Gutman and Wasylyk, 1990; Westermarck
et al, 1997).
The expression and the activity of AP-1 and ETS tran-
scription factors are induced by mitogen-activated protein
kinase (MAPK) in response to extracellular stimuli (Lewis
et al, 1998; Garrington and Johnson, 1999). MAPK, a family
of eukaryotic serine/threonine protein kinases widely con-
served among eukaryotes, play a role in the regulation of
many cellular processes such as cell proliferation, migra-
tion, and differentiation (Pearson et al, 2001). There are
presently three mammalian MAPK pathways characterized
in detail: extracellular signal-regulated kinase-1/2 (ERK1/2),
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c-Jun N-terminal kinase/stress-activated protein kinase
(JNK/SAPK), and p38 MAPK (Westermarck and Kahari,
1999). Although the p38 and JNK/SAPK pathways are ac-
tivated by cellular stress, such as UV light, osmotic shock,
and inflammatory cytokines, the ERK1/2 pathway is acti-
vated by mitogenic growth factors via Ras and by phorbol
esters via protein kinase C (Westermarck et al, 2000).
Among the MAPK subgroups, both ERK1/2 (Brauchle
et al, 2000) and p38 MAPK are known to regulate MMP-1
gene expression. More specifically, the upregulation of
MMP-1 gene expression by p38 MAPK is activated by a
variety of stimuli including interleukin-1 (Ridley et al, 1997;
Brauchle et al, 2000), C2 ceramide (Reunanen et al, 1998),
tumor necrosis factor-a (Brauchle et al, 2000), extracellular
MMP inducer (Lim et al, 1998), and okadaic acid (West-
ermarck et al, 1998).
In our previous study, we isolated a keratinocyte-derived
anti-fibrogenic factor from keratinocyte-conditioned medi-
um (KCM) and subsequently identified it as the secreted
form of stratifin, also known as 14-3-3 s, with potent MMP-
1 stimulatory effects on dermal fibroblasts (Ghahary et al,
2004). In addition, we also demonstrated that levels of stra-
tifin protein were greater in differentiated KCM as compared
with proliferating keratinocytes (Ghahary et al, 2005). Al-
though the nature of stratifin has been determined and
its collagenase stimulatory effect has been validated, the
question of its molecular mechanism by which it signals
MMP-1 induction in fibroblasts has yet to be determined.
Therefore, the purpose of this study was to identify signaling
pathway elements mediating stratifin stimulation of fibro-
blast MMP-1 expression by examining the three distinct
MAPK pathways: ERK1/2, JNK, and p38. In this study, we
show that stratifin protein increases the MMP-1 expression
in fibroblasts at the messenger ribonucleic acid (mRNA) and
protein levels and this is mediated by c-fos and p38 MAP
kinase activation.
Results
Activation of c-jun, c-fos, and MMP-1 mRNA expression
by stratiﬁn The enhancement of human MMP-1 gene tran-
scription involves activation of the AP-1 element located
around 70 in the 50-flanking regulatory region of the gene
(Westermarck and Kahari, 1999). Moreover, the induction of
expression of the principal components of the AP-1 dimers,
c-Jun and c-Fos, is mediated by distinct MAPK pathways
(Garrington and Johnson, 1999; Westermarck and Kahari,
1999). As shown in Fig 1A, treatment of dermal fibroblasts
with stratifin resulted in rapid and transient upregulation of
c-jun and c-fos mRNA levels. MMP-1 mRNA levels were
induced at 4 h of stratifin treatment. These observations
show that stratifin induction of MMP-1 gene transcription is
likely to be mediated through the AP-1 binding element.
Densitometry results revealed that stratifin markedly in-
creases c-jun and c-fos mRNA/18S ratio at 1 h followed by
dramatic induction of MMP-1 mRNA/18S ratio at 4 h in fib-
roblasts (Fig 1B).
Stratiﬁn treatment increases the MMP-1 transcriptional
rate, but not RNA stability, in dermal ﬁbroblasts To
demonstrate whether enhancement of MMP-1 mRNA ex-
pression seen in stratifin-treated fibroblasts is because of
an increase in either rate of transcription MMP-1 mRNA, its
RNA stability, or both, nuclear run-on and actinomycin D
assays were performed, respectively. The results shown in
Fig 2A indicated that stratifin markedly increased the rate of
transcription of MMP-1 mRNA. The percentage of reduction
of MMP-1 mRNA expression following actinomycin D treat-
ment in stratifin-treated fibroblasts, however, was only
slightly different from that of control cells (Fig 2B and C).
These findings clearly indicate that stratifin stimulates the
expression of MMP-1 mRNA by enhancing its promoter
activity rather than RNA stability.
Induction of MMP-1 expression by stratiﬁn is mediated
by p38 To determine the possible signal pathway in which
stratifin proteins increase the expression of MMP-1, we ex-
plored the three distinct MAPK pathways in which fibroblast
MMP-1 expression is regulated: (a) ERK1/2 (Raf ! ERK
kinase (MEK)1/2 ! ERK1/2); (b) JNK/SAPK (MEK kinase
1–3 ! MEK kinase 4 and 7 ! JNK/SAPK); and (c) p38
MAPK (MAPK kinase kinase ! MAPK kinase 3 and
6 ! p38). We examined the role of the specific MAPK
pathways in the stratifin-elicited activation of MMP-1 mRNA
expression in dermal fibroblasts by blocking MEK1/2
Figure1
Stratifin stimulates the expression of c-fos, c-jun, and matrix met-
alloproteinase-1 (MMP-1) messenger ribonucleic acid (mRNA).
Confluent human dermal fibroblasts in Dulbecco’s modified Eagle’s
medium and 2% fetal bovine serum were incubated with stratifin (2.5
mg per mL) for 0, 0.5, 1, 2, 4, 6, 12, 24 h. Total RNA (10 mg per lane) was
electrophoresed on 1% agarose gels, transferred to nitrocellulose, and
hybridized with MMP-1 cDNA. Levels of MMP-1, c-jun, and c-fos
mRNA were determined by northern blot analysis. (A) The same blots
were re-hybridized with cDNA specific for 18S ribosomal RNA and were
used as an RNA loading control. Quantitative densitometry of the ratio
of MMP-1 mRNA expression/18S ribosomal RNA with various treat-
ments is shown as a function of time (h) (B).
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and p38 MAPK pathways with chemical inhibitors previ-
ously shown to block MMP-1 gene activation by diverse
stimuli (Ridley et al, 1997; Reunanen et al, 1998; Westerm-
arck et al, 1998). As seen in Fig 3A, activation of fibroblast
MMP-1 mRNA expression by stratifin was potently inhibited
by SB203580 (SB), a specific inhibitor of p38 activity. In
parallel, blocking the activity of MEK1/2 and JNK by specific
inhibitors PD98059 (PD) and SP600125 (SP), respectively,
had no marked effect on the activation of fibroblast MMP-1
expression by stratifin.
In the same experimental setting, fibroblasts were treat-
ed with various concentrations (1, 5, 10, 50 mM) of SB in the
presence of 2.5 mg per mL of stratifin for 24 h (Fig 3B). The
results show that SB inhibits the efficacy of stratifin to in-
crease MMP-1 mRNA expression, and this inhibitory effect
is proportional to the increasing amounts of inhibitor used.
Stimulation of MMP-1 by stratifin was completely abrogated
at 50 mM of SB. This finding suggests that stratifin may
function through the p38 MAPK pathway.
p38 phosphorylation in ﬁbroblasts stimulated by strati-
ﬁn Human dermal fibroblasts were treated with stratifin (2.5
mg per mL) for different periods of time, and the activation of
p38 was determined by western blot analysis using anti-
bodies against activated forms of p38 MAPK. Figure 4A
demonstrates changes in p38 phosphorylation at 15, 30, 60,
90, 120, 240 min in fibroblasts exposed to stratifin. Rapid
and transient phosphorylation of p38 was observed at 90
min after stimulation and decreased to approximately 50%
of the maximum value by 120 min.
In the next set of experiments, the effects of SB (10 mM)
on p38 phosphorylation induced by stratifin were assessed
(Fig 4B). Consistent with the findings shown in Fig 4A, fib-
roblasts treated with stratifin for 90 min increased p38
phosphorylation and this effect was enhanced with the
treatment of SB. Densitometry results from three separate
experiments in Fig 4C indicate that in the presence of both
stratifin and SB, the level of phosphorylation was very sig-
Figure 2
Stratifin treatment increases the matrix metalloproteinase-1
(MMP-1) transcriptional rate, but not ribonucleic acid (RNA) sta-
bility, in dermal fibroblasts. (A) A representative autoradiogram of two
separate experiments obtained from hybridization of the newly syn-
thesized stratifin-treated and untreated radio-labeled RNA with either 2
or 8 mg of MMP-1 cDNA. (B) A representative of three separate au-
toradiograms of MMP-1 mRNA expression in cells initially treated with
nothing (control) or 2.5 mg stratifin for 24 h and subsequently treated
with actinomycin D at indicated time points. A representative of the
corresponding ethidium bromide stained 18 and 28 S ribosomal RNA
used as a loading control is also shown. (C) Autoradiograms and et-
hidium bromide-stained 18S ribosomal RNA from three blots prepared
from different experiments were quantified, and the ratio of MMP-1/18
S ribosomal RNA was calculated as a percent of that of 0 time point
and plotted. Solid and open bars are representative of stratifin-treated
and non-treated samples, respectively.
Figure3
Stimulation of matrix metalloproteinase (MMP)-1 expression by
stratifin is mediated by p38 mitogen-activated protein kinase
(MAPK). Fibroblasts in Dulbecco’s modified Eagle’s medium (DMEM)
and 2% fetal bovine serum (FBS) were incubated with 10 mM of specific
inhibitors for each MAPK kinase (PD98059 (PD), SB203580 (SB), and
SP600125 (SP)) for 1 h before stimulation stratifin (2.5 mg per mL) for 24
h (A). (B) Fibroblasts were treated in DMEM plus 2% FBS with 1, 5, 10,
50 mM of SB for a period of 24 h. For both sets of experiment, total
ribonucleic acid (RNA) was extracted and northern blot analysis was
performed to determine the expression of MMP-1. The same blots were
re-hybridized with cDNA specific for 18S ribosomal RNA and were used
as an RNA loading control.
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nificantly increased (p¼ 0.0001, n¼3). The effects of SB
prolonged the phosphorylated state of p38 MAPK in the
absence (po0.0001, n¼3) as well as in the presence of
stratifin treatment (po0.0001, n¼ 3). The increase of p38
MAPK phosphorylation induced by the inhibitor, however,
was more dramatic when stratifin was added (po0.005,
n¼3). These data support the effects of SB on p38 phos-
phorylation induced by KCM in which the levels of phos-
phorylation were increased in the presence of inhibitor in
addition to stimuli of MMP-1 gene expression (Moon et al,
2002).
The levels of MMP-1 protein in ﬁbroblasts are stimulated
by stratiﬁn via p38 MAPK Fibroblasts were treated with
stratifin (2.5 mg per mL) for different periods of time, and
MMP-1 protein levels were determined by western blot
analysis. The levels of b-actin were also determined in the
same samples by western blot analysis for loading controls.
Figure 5A shows the changes in MMP-1 intracellular protein
levels at 2, 4, 6, 12, and 24 h in fibroblasts stimulated by
stratifin. The results reveal an increase in collagenase pro-
tein levels starting at 4 h and reaching its peak at 12–24 h.
In the same experimental setting, the effects of SB on the
stratifin-induced MMP-1 levels were assessed by Western
blot analysis (Fig 5B). Fibroblasts were treated for 24 h with
2.5 mg per mL of stratifin, 10 mM of SB, or a combination of
both. Once again, our data indicate that intracellular MMP-1
protein levels are significantly increased after 24 h treatment
with stratifin (po0.005, n¼3). As expected, p38 MAPK
inhibitor blocked the stratifin induction of MMP-1 protein
levels. In Fig 5C, densitometry results from three separate
experiments revealed very significant differences in MMP-1
levels between stratifin and stratifin plus SB-treated sam-
ples (po0.005, n¼ 3).
Microarray analysis of MAPK signaling pathway genes
of stratiﬁn-treated ﬁbroblasts Figure 6 shows array re-
sults of MAPK signaling pathway gene expression in un-
treated and stratifin-treated fibroblasts. Expression is
normalized for cyclophilin A (PPIA). Compared with untreat-
ed samples, stratifin-treated fibroblasts revealed an in-
crease in the levels of Elk4/Sap1a and autotoxin (ENPP2)
expression by 3.5- and 4.75-fold, respectively (Fig 6B).
Figure 4
Stratifin induces p38 mitogen-activated protein kinase (MAPK)
phosphorylation in dermal fibroblasts. Fibroblasts were treated with
stratifin (2.5 mg per mL) for various time intervals as indicated. The
levels of activated p38 (p-p38) were determined by western blot anal-
ysis using phospho-specific antibodies for p38 MAPK. The levels of
total p38 were also determined in the same samples by western blot
analysis using specific antibodies. C6 cell extracts treated with an-
isomycin were used as positive control for phospho-p38 (A). (B) Fib-
roblasts were treated with either stratifin (2.5 mg per mL), SB203580
(SB) (10 mM), or a combination of both. Fibroblasts were pretreated with
SB (10 mM) for 1 h before treatment with stratifin. The membrane was
immunoblotted using antibodies against total and phosphorylated
forms of p38 MAPK and subsequently immunoblotted with b-actin an-
tibody as loading control. Quantitative densitometry of the ratio of in-
tracellular p-p38 MAPK protein/total p38 MAPK protein was performed
and is shown in (C). All p-values less than 0.005 represent very sig-
nificant differences.
Figure5
Stimulation of intracellular matrix metalloproteinase (MMP)-1 pro-
tein levels by stratifin is mediated by p38 mitogen-activated pro-
tein kinase. Fibroblasts were treated with stratifin (2.5 mg per mL) for
different periods of time as indicated (A). The intracellular MMP-1 pro-
tein levels were determined by western blot analysis using specific
antibodies. The levels of b-actin were also determined in the same
samples by western blot analysis for loading controls. (B) Fibroblasts
were treated for 24 h with nothing (N), stratifin (s), SB203580 (SB), or a
combination of both (sþSB). Fibroblasts were pretreated with SB for 1
h before treatment with 14-3-3 s. b-actin is shown as loading controls.
Quantitative densitometry of the ratio of intracellular MMP-1 protein/b-
actin was performed and is shown in (C). The values of po0.05
and po0.005 represent significant and very significant differences,
respectively.
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Interestingly, Elk4/Sap1a is a transcription factor with the
ability to form a ternary nucleoprotein complex with the
serum response factor (SRF) over the serum response
element (SRE) (Buchwalter et al, 2004). The SRE is consti-
tutively occupied by a protein complex comprising of SRF
and ternary complex factor (TCF) and pivotal for transcrip-
tional upregulation of the c-fos protooncogene, whose gene
product is an essential AP-1 component of modulation in
MMP-1 gene expression. To confirm the array results,
northern analysis of Elk4/Sap1a mRNA and 18S rRNA ex-
pression was performed on total RNA samples extracted
from fibroblasts that were treated with 2.5 mg per mL of
stratifin for the various time intervals. Figure 7 demonstrates
changes in Elk4/Sap1a mRNA expression at 0, 0.5, 2, 4, 6,
12, 24 h in fibroblasts exposed to stratifin. Upregulation of
Elk4/Sap1a expression was observed at 0.5 h after stimu-
lation and peaked in intensity at 4 h and subsequently de-
creased to approximately 50% of the maximum value by
6 h. This finding reveals that stratifin markedly increases
Elk4/Sap1a mRNA expression in a time-dependent fashion
in fibroblasts.
Discussion
This study explored the mechanism by which stratifin in-
creases the expression of MMP-1 mRNA in dermal fibro-
blasts. Interaction of AP-1 complex with the promoter
region of human MMP-1 gene is critical for activation of
MMP-1 gene transcription in response to a variety of ex-
tracellular signals (Westermarck and Kahari, 1999). For this
reason, here, we have evaluated the levels of c-jun and
c-fos, two elements of the AP-1 complex, in response
to stratifin treatment of fibroblasts. Our findings show a
marked increase in c-jun and c-fos mRNA expression within
one hour of stratifin treatment. An increase in the levels of
two members of AP-1 complex suggests that stratifin more
likely stimulates MMP-1 mRNA expression through its pro-
moter activity. In fact, our results of the nuclear run-on as-
say clearly indicate that this enhancement might well be
because of an increase in the transcriptional rate of MMP-1
mRNA rather than its RNA stability.
The expression and the activity of AP-1 and ETS tran-
scription factors are induced by MAPK in response to
extracellular stimuli (Lewis et al, 1998; Garrington and
Johnson, 1999). The activated MAPK mediate extracellular
signals, which regulate cell growth, survival, differentiation,
and death. At present, three distinct MAPK pathways de-
scribed in detail from the literature are ERK1/2, JNK/SAPK,
and p38 MAPK (Westermarck and Kahari, 1999). Specific
upstream dual-specificity kinases (MAPK kinases) are able
to phosphorylate the conserved threonine and tyrosine res-
idues of MAPK, which in turn phosphorylate and activate
nuclear protein kinases such as MAPK-activated protein
kinases 1, 2, 3 or transcription factors including c-Jun, Elk-
1, and activating transcription factor-2 (Westermarck and
Kahari, 1999). A series of MAP kinase nuclear substrates
including those directly involved in MMP-1 transcriptional
regulation such as the gene products of c-fos and c-jun
oncogenes compose the AP-1 transcriptional factor (Angel
et al, 1987a, b; Hunter and Karin, 1992; Hill and Treisman,
Figure 6
Microarray analysis of messenger ribonucleic acid (mRNA) ex-
tracted from stratifin-treated fibroblasts. Fibroblasts were treated
with stratifin (2.5 mg per mL) for 90 min. Total mRNA was extracted,
reverse-transcribed, and the corresponding cDNA biotin-labeled ac-
cording to the manufacturer’s directions. (A) Shows the results of un-
treated and stratifin-treated samples of MAP kinase signaling pathway
gene array. Cyclophilin A or peptidylprolyl isomerase A (PPIA) expres-
sion was used as positive control and the DNA of PUC18 plasmid was
used as negative control. The highlighted box illustrates the expression
of Elk4/Sap1a and autotaxin (ENPP2). A key to gene coordinates is also
shown in (B) in addition to a table indicating the fold increases of Elk4/
Sap1a and autotaxin from stratifin treatment.
Figure7
Confirmation of array results by northern analysis of Elk4/Sap1a.
Fibroblasts were treated with stratifin (2.5 mg per mL) for different time
intervals. The total ribonucleic acid (RNA) was extracted and northern
blot analysis was performed to determine the expression of Elk4/
Sap1a. The same blot was re-hybridized with cDNA specific for 18S
ribosomal RNA and was used as an RNA loading control.
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1995). AP-1 is activated by a variety of signaling cascades,
some of which are p38 dependent (Hazzalin et al, 1997).
In this study, keratinocyte-derived stratifin protein was
purified and added to fibroblast to induce MMP-1 mRNA
expression and this is shown to be mediated by p38 MAP
kinase. In addition, blocking the p38 pathway with SB
inhibits the upregulation of endogenous MMP-1 gene ex-
pression by exogenous stratifin. These observations are in
accordance with the previous study performed by Moon
et al (2002), in which fibroblasts exposed to KCM induced
MMP-1 mRNA expression through p38 MAPK pathway.
They also demonstrated that p38 signaling inhibitor (SB)
blocked MMP-1 elaboration induced by KCM. According to
our study, we found that fibroblasts treated with p38 signa-
ling inhibitor, SB, increased the levels of phosphorylated
forms of p38 MAPK. This finding was consistent with that
reported by Moon et al (2002). These investigators demon-
strated a greater increase in the levels of p38 phosphory-
lated MAPK upon treatment of cells with KCM plus SB
relative to that treated with KCM alone. Although the rea-
son(s) for this increase is not known, there are several pos-
sibilities to explain this finding. Firstly, as reported by
Schliess et al (1998), cells treated with SB not only inhibited
the interaction of MAPK to its substrates, it also inhibi-
ted the MAP kinase phosphatases (MKP), involved in
dephosphorylation of activated MAPK protein. As such,
inhibition of dephosphorylation would result in the accu-
mulation of phosphorylated forms of MAPK as seen in our
study. In fact, the study by Moon et al (2002) also showed
that the level of phosphorylated p38 MAPK in SB-treated
cells remained high for a longer duration relative to that of
untreated cells. This may indicate that activated p38 MAPK
is more resistant to dephosphorylation in the presence of
this inhibitor. Secondly, inhibition of downstream activity of
p38 MAPK by SB may preclude the effects of MKP, which
are normally activated after MAPK phosphorylation, as a
mechanism for inactivation of the stimuli-induced signal
cascades (Chu et al, 1996; Haneda et al, 1999; Hutter et al,
2000). MKP-1, for example, is rapidly transcriptionally in-
duced by the same stimuli that activate MAPK (Schliess
et al, 1998; Lasa et al, 2002). It is also capable of dephos-
phorylating all three MAPK families, ERK, p38, and JNK
(Franklin and Kraft, 1997; Slack et al, 2001; Theodosiou and
Ashworth, 2002).
Other studies have also identified the expression of fib-
roblast MMP-1 to be dependent on p38 MAPK expression
(Lim et al, 1998; Westermarck et al, 1998; Brauchle et al,
2000). Having said that, the timing at which c-fos mRNA is
expressed is slightly different from that of p38 MAPK phos-
phorylation. There are at least two different reasons to ex-
plain this. Firstly, as homo-dimerization of c-jun can also
form AP-1 complex (Wagner, 2002), one may speculate that
p38 MAPK-activated c-jun is responsible for MMP-1 pro-
moter activity. Secondly, the 30 min time difference may
well be because of inter-experimental variations frequently
seen when the results of two completely different experi-
ments, the northern analysis of c-fos and c-jun mRNA
expression and phosphorylation of p38 MAPK assay, are
compared.
Moreover, p38 MAPK has been implicated to mediate the
expression of several other metalloproteinase genes impor-
tant in ECM remodeling including, MMP-9 (Simon et al,
1998) and MMP-3 (Ravanti et al, 1999). Originally described
to be a stress-activated enzyme (Han et al, 1994), p38 has
also been shown to have downstream effects on actin fil-
ament rearrangement (Rousseau et al, 1997), transcription
factor activation (Rousseau et al, 1997), and matrix degra-
dation (Lim et al, 1998; Simon et al, 1998; Westermarck
et al, 1998; Ravanti et al, 1999). Based on these observa-
tions, p38 may become an important MAP kinase in the
general process of tissue remodeling. In addition, specific
inhibitors of p38 MAPK pathway may eventually serve as
novel therapeutic agents for inhibiting degradation of col-
lagenous ECM.
According to our microarray results, stratifin upregulates
Elk4/Sap1a transcription factor (Fig 6). This finding was fur-
ther confirmed by northern blot analysis (Fig 7). The ETS
domain transcription factor, Sap1a, belongs to a family of
TCF and has high homology with Elk-1 (Buchwalter et al,
2004). Sap1a contains a MAP kinase docking domain that
exhibits strong sequence similarity to the Elk-1 D-domain
(Galanis et al, 2001). Although Sap1a has been shown to be
able to act as a target of the ERK, JNK, and p38 MAPK
families (Janknecht et al, 1995; Price et al, 1995; Janknecht
and Hunter, 1997a, b), Sap1a is preferentially phosphory-
lated by p38a MAPK on the homologous residues, Ser381
and Ser387, indicating that specificity determinants exist.
Mutation of these sites to alanine severely reduces c-fos
SRE-dependent transcription mediated by Sap1a and p38
MAPK (Janknecht and Hunter, 1997a). The kinase selectivity
of Sap1 is determined by its D-domain (Galanis et al, 2001).
Sap1a requires DNA-bound SRF for ternary complex for-
mation and makes extensive DNA contacts to the 50 side of
SRF, but does not bind DNA autonomously. Moreover,
Sap1a interacts with the SRE in the absence of SRF, al-
though cooperative binding of Sap1 with SRF is observed
(Dalton and Treisman, 1992). If this is the case, the presence
of serum would be required for stratifin to regulate c-fos
transcription and thus induce MMP-1 gene expression. The
results in our laboratory support this phenomenon since the
stratifin fails to increase MMP-1 gene expression in fibro-
blasts in the absence of serum (data not shown).
In conclusion, we have characterized that stratifin protein
stimulates the signal pathway of fibroblast MMP-1 expres-
sion by activation of the promoter, mRNA, and protein lev-
els. Our data suggest that the enhancement of fibroblast
mRNA expression as well as protein levels by keratinocyte-
released stratifin protein is mediated by p38 MAPK. Acti-
vated p38 MAPK is then able to phosphorylate and activate
Elk4/Sap1a in response to stratifin to induce c-fos gene
transcription and subsequently form AP-1 components to
modulate MMP-1 gene expression and intracellular protein
levels. These data indicate that keratinocyte-derived stra-
tifin proteins modulate fibroblast MMP-1 levels through the
MAPK pathway, leading to altered expression of key bio-
logical functions.
Materials and Methods
Fibroblast cell culture Following informed consent, skin punch
biopsies were obtained from patients undergoing elective recon-
structive surgery, under local anesthesia, according to a protocol
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approved by the University of Alberta Hospitals Human Ethics
Committee. The study was carried out in accordance with the
principles of the Declaration of Helsinki (World Medical Association
of Helsinki, Somerset West, 1996). Cultures of human dermal fib-
roblasts were established as described previously (Ghahary et al,
1992). In brief, punch biopsy samples were prepared from human
adult dermal fibroblasts. The tissue was collected in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Grand Island, New York)
plus 10% fetal bovine serum (FBS) supplemented with an antibi-
otic–antimycotic preparation (100 U per mL penicillin, 100 mg per
mL streptomycin, 0.25 mg per mL amphotericin B) (Gibco). Spec-
imens were dissected and minced into small pieces less than
0.5 mm in diameter, washed six times with DMEM, and distributed
into 60  15 mm culture dishes (Corning, Corning, New York),
four pieces per dish. After 4 weeks of incubation, the cells were
released from dishes by brief treatment with 0.1% trypsin (Life
Technologies, Gaithersburg, Maryland) and 0.02% ethylenedia-
minetetraacetic acid (EDTA) (Sigma, St Louis, Missouri) in phos-
phate-buffered saline (PBS) (pH 7.4) and reseeded into 75 cm2
flasks (Corning). Upon reaching confluence, the cells were sub-
cultured at a ratio of 1:6 by trypsinization. Fibroblasts from pas-
sages three to eight were used for this study.
Preparation of human recombinant stratiﬁn (14-3-3 r) Proce-
dures of human recombinant 14-3-3 s protein preparation were
established as described previously (Ghahary et al, 2004). Briefly,
the cDNA of 14-3-3 s from human keratinocytes was cloned into
pGEX-6P-1 expression vector (Amersham/Pharmacia Biotech, Pi-
scataway, New Jersey) and transformed into protein expressing
bacteria, BL-21 (DE3) (Novagene, Madison, Wisconsin). A single
positive clone was grown in 100 mL of LB medium containing 50
mg per mL of ampicillin for 4–6 h at 291C until an OD600 nm of
0.4–0.6 was reached. Bacteria were then diluted to 1:10 with LB
medium plus 0.1 mM IPTG for 12 h. To purify the protein, bacteria
were centrifuged and lysed with 50 mM Tris-HCl (pH 7.4) contain-
ing 10 mM EDTA, 5mM EGTA, protease inhibitor cocktail (Sigma),
1% Triton X-100, and 0.5% IGEPAL CA630. Cell lysate was passed
through a glutathione sepharose 4B affinity column and subse-
quently washed with PBS containing 0.1% Triton X-100 until an
OD280 nm reached zero. GST-fused 14-3-3 s was digested using
PreScission protease according to the manufacturer’s proce-
dure (Amersham/Pharmacia Biotech). GST-free 14-3-3 s was
then eluted, dialyzed against PBS, and then concentrated with
Centricon (Millipore Corporation, Bedford, Massachusetts). The
sequence of protein was validated on a Bruker REFLEX III mass
spectrometer (Bruker Daltonics Bremen/Leipzig, Germany) using
MALDI in positive ion mode.
Treatment of ﬁbroblasts Fibroblasts were seeded into 60  15
mm petri dishes (Corning). For each experiment, confluent fibro-
blasts were rinsed with PBS before DMEM plus 2% FBS was
added. At this time, 2.5 mg per mL of recombinant stratifin was
added and incubated for 24 h to stimulate collagenase mRNA ex-
pression. For the inhibition of ERK1/2, p38, and JNK MAPK, 10 mM
of specific inhibitors for each kinase (PD, SB, and SP, respectively)
were added 1 h before stimulation. MEK1/2 inhibitor PD, p38 in-
hibitor SB, and JNK inhibitor SP were purchased from Calbiochem
(San Diego, California). For western blot analysis of total and
phosphorylated forms of p38 MAPK protein levels, confluent fib-
roblasts were switched to serum-free media for 24 h before treat-
ment in order to reduce the background phosphorylation levels of
MAPK because of serum.
Nuclear run-on and RNA stability assays The nuclei were pre-
pared using a modified procedure described before (Ghahary et al,
1998). Briefly, fibroblast cell layers were harvested by scraping in
ice-cold PBS, centrifuged, washed with a resuspension buffer
(10 mM Tris, 10 mM NaCl, 5 mMMgCl2, pH 7.4), and recentrifuged.
The cell pellet was resuspended in the same buffer containing
0.5% (v/v) NP40 (Nonidet) and the nuclei were isolated by centrif-
ugation. Isolated nuclei were then resuspended in nuclear freezing
buffer (50 mM Tris, pH 8.0, 5 mM MgCl2, 0.5 mM DTT, and 40%
glycerol), counted, and stored in liquid nitrogen until use. In vitro,
nuclear run-on transcription was accomplished according to a
modified protocol of Greenberg and Ziff (1984). Each reaction typ-
ically contained 5  107 nuclei (210 mL), 250 mCi [a-32P] UTP, 0.33
mM ATP, CTP, and GTP, in a final volume of 295 mL. The reaction
mixture was incubated for 30 min at 301C with intermittent shaking.
To isolate the radio-labeled RNA, the reaction mixture was treated
with RNase-free DNase I for 5 min at 301C followed by treatment
with proteinase K (100 mg) for 30 min at 451C. The radio-labeled
RNA was then extracted and autoradiography of the autoradio-
graphs was performed using the procedures described under
northern blot analysis.
To evaluate mRNA stability for MMP-1 in response to stratifin
treatment, confluent fibroblasts were treated with either nothing
(control) or 2.5 mg per mL of stratifin for 24 h. One set of either
treated or untreated cells was harvested and assigned as 0 time
point. Cells were then treated with actinomycin D at a final con-
centration of 5 mg per mL. Untreated and treated cells were then
harvested at 30, 60, 180, or 360 min post-treatment and the total
RNA from each time point was individually extracted and subjected
to northern blot analysis by the procedures described in the
following section.
RNA isolation and Northern blot analysis Fibroblasts were har-
vested with 400 mL of 4 M guanidium isothiocyanate (GITC) so-
lution, and total RNA from each group was isolated by the acid–
guanidium–phenol–chloroform method (Ghahary et al, 1998). Total
RNA from each individual fibroblast culture was then separated by
electrophoresis (10 mg per lane) on a 1% agarose gel containing
2.2 M formaldehyde and was blotted onto a nitrocellulose mem-
brane (Bio-Rad Laboratories, Hercules, California). The blots were
baked for 2 h at 801C under vacuum and prehybridized for 4 h at
451C in a prehybridization solution. Hybridization was performed at
451C in the same solution, using collagenase, c-fos, c-jun, Elk4/
Sap1, or 18S ribosomal RNA cDNA probes. The cDNA probes
were labeled with P-a32-dCTP by nick translation. The filters were
washed initially at room temperature with 2  sodium citrate/so-
dium chloride buffers and 0.1% sodium dodecyl sulfate (SDS) for
1 h and finally washed for 20 min at 651C in 0.1X sodium citrate/
sodium chloride buffer and 0.1% SDS. Autoradiography was per-
formed by exposing a Kodak X-Omat film to nitrocellulose filters at
801C in the presence of an intensifying screen. Quantitative anal-
ysis of autoradiographs was accomplished by densitometry. Each
experiment was performed at least twice to ensure reproducibility
of the results.
The cDNA probes for collagenase, c-fos, c-jun, and 18S rib-
osomal RNA were obtained from the American Type Culture Col-
lection (Rockville, Maryland). The cDNA probe for Elk4/Sap1 was
obtained by extracting fibroblast total RNA and was amplified by
RT-PCR. The PCR product was then purified and ligated into a
pGEX-6P-1 vector (Amersham/Pharmacia Biotech). The ligated
products were then transformed to competent DH5a cells with the
regular heat-shock transformation method. Positive clones were
identified by the size of restriction enzyme-digested products. DNA
sequence was confirmed by fluorescence dNTP sequence analysis.
Cell protein lysate extraction and Western blot analysis Cell
extracts were prepared from 1.5  106 cells in lysis buffer (20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100,
10% glycerol, 100 mM PMSF, protease inhibitor cocktail, and
Na3VO4 to prevent dephosphorylation of p38 (Sigma Chemicals)).
Extracts were centrifuged at 13,000 r.p.m. (16,000 g) for 10 min.
The total protein contents of cell lysate were determined by the
bovine serum albumin (BSA) assay (Pierce, Rockford, Illinois).
Equivalent amounts of fibroblasts extract (100 mg per lane)
were resolved by 12% SDS polyacrylamide gel electrophoresis
(SDS-PAGE) and electrotransferred onto PVDF membranes (Milli-
pore Corporation).
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For the detection of p38 MAPK, rabbit IgG antibodies to total
and phosphorylated forms of p38 were obtained from Cell Signa-
ling (Beverly, Massachusetts). The membranes were blocked in 5%
skim milk powder in PBS 0.1% Tween 20 for 2 h at room temper-
ature. Membranes were then treated overnight at 41C with
antibodies to total or phosphorylated forms of the signaling inter-
mediates (1:1000 dilutions) in PBS 0.1% Tween 20 plus 5% BSA.
Following several rinses in PBS 0.1% Tween 20 for 30 min, the
membranes were then incubated with the appropriate secondary
horseradish peroxidase-conjugated anti-rabbit IgG (Bio-Rad Lab-
oratories) (1:2500 dilution). Immunoreactive proteins were then
visualized using the ECLþplus western blotting detection system
(Amersham Biosciences, Buckinghamshire, UK).
For the detection of collagenase and b-actin protein levels, cell
lysates (40 mg per lane) from each treatment were subjected to
SDS-PAGE analysis with 12% (wt/vol) acrylamide gel, and elect-
rotransferred onto PVDF membranes (Millipore Corporation). The
membranes were blocked in 5% skim milk powder in PBS 0.1%
Tween 20 overnight. Immunoblotting was performed using 2 mg per
mL of mouse anti-human MMP-1 monoclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, California), or 2 mg per mL of mouse
anti-human b-actin monoclonal antibody (Santa Cruz Biotechnol-
ogy). The membranes were then incubated with the appropriate
secondary horseradish peroxidase-conjugated anti-mouse IgG
(Jackson ImmunoResearch Laboratories, West Grove, Pennsylva-
niA) antibodies (1:2500 dilution). Immunoreactive proteins were
then visualized using the ECLþplus western blotting detection
system (Amersham Biosciences).
Microarray experiments To examine whether stratifin induced
other genes involved in the MAPK signaling pathway, GEArray
gene expression array systems were purchased from SuperArray
Bioscience Corporation (Bethesda, Maryland). Each GEArray Q
Series Human MAP Kinase Signalling pathways gene array con-
sists of 96 genes known to be involved in MAPK pathways as well
as control sequences (PUC18 plasmid DNA as negative control; b-
actin, PPIA, and glyceraldehydes 3 phosphate dehydrogenase
(GAPDH) for loading). Using different arrays, we compared the
gene expressions of untreated and stratifin-treated fibroblasts. For
these experiments, total cellular RNA was isolated by a modifica-
tion of the GITC technique. The integrity of RNA was assessed by
visualization of ethidium bromide-stained gels. The microarrays
were used according to the manufacturer’s instructions. In brief,
using the reagents provided, cDNA was prepared from total RNA
by reverse transcription with MMLV reverse transcriptase, biotiny-
lated with Biotin-16-dUTP (Roche, Indianapolis, Indiana), and
then hybridized under precisely specified conditions to a positive-
ly charged nylon membrane containing the arrayed DNA. The ar-
rays were visualized using the chemiluminescent detection system
purchased from GEArray (Bethesda, Maryland). Loading was ad-
justed based on the intensity of hybridization signals to the house-
keeping gene, PPIA, and then gene expression was quantified by
scanning densitometry.
Statistical analysis Autoradiograms of northern analysis were
quantified with densitometry, and data were expressed as a rel-
ative OD value. The statistical significance of differences in MMP-1
mRNA expression between treated and untreated dermal fibro-
blasts was tested with Student’ unpaired two-tailed t test; p-values
o0.05 ando0.01 were considered significant and very significant,
respectively.
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